Sales of Anemia Drugs May Be Hurt by New Recommendations

The National Kidney Foundation said Thursday it plans to cut its recommended target for hemoglobin levels in kidney disease patients -- a move that could hurt sales of lucrative anemia drugs that boost hemoglobin but have come under scrutiny over safety concerns.

The changes could hurt sales of Amgen key anemia drugs Aranesp and Epogen, which brought in $6.6 billion in 2006, and Johnson & Johnson's

Procrit, which saw $3.2 billion in sales, although some analysts say that drug has become a less-critical product for the company.

Contact U.S. News


    Get the best of CNBC in your inbox

    Please choose a subscription

    Please enter a valid email address
    To learn more about how we use your information,
    please read our Privacy Policy.

Don't Miss

  • The Glass Ceiling

    Full-time working women still only earn about 77% of what men do in the same fields. A lawsuit in Silicon Valley is bringing renewed focus to that statistic. Vanity Fair Contributing Editor Bethany McLean on the equality fight for women's pay and promotion.

  • Man takes off work clothes on beach

    With Ruth Porat leaving Wall Street for Silicon Valley, Turney Duff takes a look at other ex-Wall Street friends and where they are now.

  • A group of scientists believe they've cracked the reason behind a big mystery: Why are beards so popular?

U.S. Video